BioSpace News Archive

Stilla Technologies, a leading provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analyses, just announced it will be joining an initiative led by Yuzi Holdings and TusPark Science & Technology Service Group (TusPark) to donate two Naica Systems to City of Zhengzhou and City of Xinyang², in China, to help them better detect the coronavirus and monitor its mutations.

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented new results for continuous glucose monitor-based glucose predictions at The 13th International Conference on Advanced Technologies & Treatments for Diabetes in Madrid, Spain

Certara®, the global model-informed drug development and decision support leader, today reported that it has acquired a range of modeling and simulation technology assets from In Silico Biosciences, Inc.

Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 5:40 a.m. Pacific / 8:40 a.m. Eastern on Tuesday, March 3, 2020, at Cowen and Company’s 40th Annual Health Care Conference in Boston.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present a corporate overview and an update on the DEXTENZA® launch and Michael Goldstein, M.D., M.B.A., Chief Medical Officer of Ocular Therapeutix will provide an update

Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s CEO, will present at the following investor conferences:

Study shows Cost Increases for Manufacturers could range from 400 percent to 2,000 percent

Feb. 25, 2020 13:30 UTC X4 Pharmaceuticals to Present at Two Upcoming Investor Conferences in March CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team will present and conduct one-on-one meetings at Cowen and Company’s 40th Annual Health Care Conference and Oppenheimer’s 30th Annual H

TUCSON, Ariz. , Feb. 25, 2020 /PRNewswire/ -- Emagine Solutions Technology, an award-winning medical software device company located in Tucson , announced that it has received clearance from the U.S. Food & Drug Administration (“FDA”) to market its VistaScan mobile ultrasound platform. The VistaScan platform transforms a clinician’s cell phone or tablet into a port